Scientific Program - Epilepsy

Section Heads: Francisco Sales, Portugal & Michael Sperling, USA
Please see below the CONy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable / overview, please click here
For the full Scientific Program, please click here >
Chairs: Nuno Canas, Portugal; Thanos Covanis, Greece
08:30-09:25 Proposition: Carbamazepine (CBZ) is an outmoded drug and should never be used as a first-line therapy
Capsule: CBZ is an effective antiepileptic drug, advocated by the ILAE as a first-line agent. However, studies in recent years have elucidated new risks and problems associated with its prescription. Should it remain listed as a first-line agent, or should it be relegated to secondary or tertiary use once other agents have failed?
08:30-08:40 Host: João Chaves, Portugal
08:40-08:55 Pro: Martin Brodie, UK
08:55-09:10 Con: Cigdem Ozkara, Turkey
09:10-09:25 Discussion and rebuttals
09:25-10:20 Can we predict with reasonable confidence which patients with idiopathic generalized epilepsy (IGE) will remit?
Capsule: These are often considered benign and liekly to remit.  Is this true?  Do some patients require lifetime treatment and can one predict who they are? This will require a review of the different syndromes and discussion of prognosis
09:25-09:35 Host: Alla Guekht, Russia
09:35-09:50 Yes: Elinor Ben Menachem, Sweden
09:50-10:05 No: Martin Holtkamp, Germany
10:05-10:20 Discussion and rebuttals
10:35-12:25 Session 22 | DIAGNOSTIC EVALUATION
Chairs: Nandan Yardi, India; Francisco Sales, Portugal
10:35-11:30 Should we regularly check for autoimmune causes in patients with refractory epilepsy without other obvious causes?
Capsule: Autoimmune disorders are increasingly being recognized; how often should we check for these? This will require discussion of the different types of autoimmune epilepsies, epidemiology, diagnostic criteria, treatment and economic considerations
10:35-10:45 Host: Ilan Blatt, Israel
10:45-11:00 Yes: Alla Guekht, Russia
11:00-11:15 No: William Theodore, USA
11:15-11:30 Discussion and rebuttals
11:30-12:25 Can the Wada test be replaced by fMRI and other techniques?
Capsule: The Wada test has been used for decades to lateralize the language dominant hemisphere and assess memory in advance of epilepsy surgery, particularly for mesial temporal resections. However, it poses risk and causes discomfort, and its value in predicting postoperative amnesia has not been validated. fMRI tasks have been developed to localize and lateralize language and memory. Can this non-invasive test replace the Wada test?
11:30-11:40 Host: Isabel Santana, Portugal
11:40-11:55 Yes: Michael Sperling, USA
11:55-12:10 No: Cigdem Ozkara, Turkey
12:10-12:25 Discussion and rebuttals
Chairs: Makarand Bagul, UK; Jose Lopes Lima, Portugal
15:00-16:00 Should combination therapy be used after failure of monotherapy with one or two antiepileptic drugs?
Capsule: How many drugs should be tried in monotherapy before resorting to combination therapy, given the variety of mechanisms to try with different therapeutic agents?
15:00-15:10 Host: Manjari Tripathi, India
15:10-15:25 Yes: Martin Brodie, UK
15:25-15:40 No: Elinor Ben Menachem, Sweden
15:40-16:00 Discussion and rebuttals
16:00-17:00 Should responsive neurostimulation be offered in preference to other forms of neurostimulation when a well defined focus is known?
Capsule: A variety of neurostimulation techniques are now available, including, responsive neurostimulation, vagus nerve stimulation, and trigeminal nerve stimulation. Responsive neurostimulation is the only technique that provides stimulation directly at the location of the presumed epileptic focus. Is this method superior?
16:00-16:10 Host: Michael Sperling, USA
16:10-16:25 Yes: Michael Sperling, USA
16:25-16:40 No: Martin Holtkamp, Germany
16:40-17:00 Discussion and rebuttals
17:15-19:00 Session 24 | EPILEPSY TREATMENT II
Chair: Konrad Rejdak, Poland
17:15-18:10 Debate: Should non-convulsive status epilepticus be treated aggressively?
Capsule: How harmful is non-convulsive status? Is there really evidence to support aggressive therapy? What about risks of therapy, data regarding prognosis?
17:15-17:25 Host: Ivan Rektor, Czech Republic
17:25-17:40 Yes: Manjari Tripathi, India
17:40-17:55 No: Ilan Blatt, Israel
17:55-18:10 Discussion and rebuttal
Moderators: Francisco Sales, Portugal & Michael Sperling, USA
SUNDAY, MARCH 20, 2016
Chair: Sadagat Huseynova, Azerbaijan
11:30-12:00 Beyond the horizon in epilepsy
Michael Sperling, USA